All studies on T1D have used once-weekly injectable semaglutide
This guide is designed for: Before comparing GLP-1 medications and bariatric surgery directly, it helps to understand how each approach works and how they support weight management differently
Studies in mice showed that pharmacological blockade or genetic knockout of GLP1Rs in the central nervous system (CNS) could block or significantly attenuate GLP1RA weight loss and food intake suppression, highlighting the necessity of central GLP1Rs 69
For example, one study showed that in people with type 2 diabetes, treatment with semaglutide (1 mg weekly) causes an average loss of about 6% of body weight over 40 weeks, while treatment with tirzepatide (15 mg/week) leads to an 11% weight loss in this population
A British Medical Journal publication says its unlikely to happen in 2024
If you are interested in making a positive impact in your life, you need to come here